A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)

Launched by THE CHRISTIE NHS FOUNDATION TRUST · Jun 6, 2023

Keywords

ClinConnect Summary

The MIDSECTION trial is a study looking at a new way to treat abdominal and lung cancers using a special type of radiation therapy called MRI-guided stereotactic ablative radiotherapy. This method aims to deliver precise and strong radiation to tumors while minimizing harm to nearby healthy organs. The study will help researchers understand how well this technique works and if it can be safely used in patients.

To participate in this trial, candidates must be between the ages of 65 and 74, have no issues that prevent them from undergoing MRI scans, and meet certain health criteria related to their cancer treatment. They should also be able to give consent and have a life expectancy of more than six months. If selected, participants can expect to receive focused radiation treatment and will need to attend follow-up appointments for at least a year to monitor their health. It's important to note that this study is not yet recruiting participants, so those interested will need to wait for it to start.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Have no MRI contra-indications.
• • 2. Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines.
• • 3. Be able to give informed consent.
• • 4. Anticipated life-expectancy \> 6 months.
• • 5. Not more than 3 oligmetastatic sites treated in total per patients.
• • 6. Performance status ≤ 2.
• • 7. Willing to attend follow-up and have details collected on prospective basis for a minimum of 1 year.
• Exclusion criteria:
• • 1. Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
• • 2. Unable to tolerate MRI scans.
• • 3. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study.
• • 4. Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
• • 5. Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).